Fig. 1From: Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapyKaplan-Meier curves for the DFS outcomes among patients with trastuzumab. Patients with low pre-NLR values (group 2) showed higher 3-year DFS compared with that with high pre-NLR values (group 3) (p = 0.003). DFS, disease-free survival; pre-NLR, pretreatment neutrophil/lymphocyte ratioBack to article page